Assessing serum levels of SM22α as a new biomarker for patients with aortic aneurysm/dissection.

ABSTRACT:

Background

Aortic aneurysm/dissection (AAD) is now encountered more often because of the increasing prevalence of atherosclerosis and hypertension in the population. Despite many therapeutic improvements, in particular timely and successful surgery, in-hospital mortality rates are still higher. Timely identification of patients at high risk will help improve the overall prognosis of AAD. Since early clinical and radiological signs are nonspecific, there is an urgent need for accurate biomarkers. Smooth muscle 22α (SM22α) is a potential marker for AAD because of its abundant expression in vascular smooth muscle, which is involved in development of AAD.

Methods

We prepared three different mouse models, including abdominal aortic aneurysm, neointimal hyperplasia and atheroscler

SUBMITTER: Zhang N 

PROVIDER: S-EPMC8970406 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature